FILE PHOTO: A robotic DNA sample automation machine works on DNA samples at a Regeneron Pharmaceuticals Inc. laboratory at the biotechnology company's headquarters in Tarrytown, New York, U.S., March 24, 2015. REUTERS/Mike Segar/File Photo
LONDON (Reuters) - Scientists are getting closer to building life from scratch and technology pioneers are taking notice, with record sums moving into a field that could deliver novel drugs, materials, chemicals and even perfumes.
Despite ethical and safety concerns, investors are attracted by synthetic biology's wide market potential and the plummeting cost of DNA synthesis, which is industrialising the writing of the genetic code that determines how organisms function.
